Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. by Taylor, CF et al.
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Frequent inactivatingmutations ofSTAG2 in bladder
cancer are associated with low tumour grade and
stage and inversely related to chromosomal copy
number changes
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Inactivating mutations of STAG2 have been reported at low frequency in several cancers. In glioblastoma, the
function of STAG2 has been related to maintenance of euploidy via its role in the cohesin complex. In a
screenof a largeseriesofbladder tumoursandcell lines,we found inactivatingmutations (nonsense, frameshift
andsplicing) in 67of 307 tumours (21.8%) and6of 47cell lines. Thirteenmissensemutationsofunknownsignifi-
cance were also identified. Inactivating mutation was associated with low tumour stage (P 5 0.001) and low
grade (P 5 0.0002). There was also a relationship with female patient gender (P 5 0.042). Examination of copy
number profiles revealed an inverse relationship of mutation with both fraction of genome altered and whole
chromosomecopynumberchanges. Immunohistochemistry showed that in themajorityof caseswith inactivat-
ing mutations, STAG2 protein expression was absent. Strikingly, we identified a relatively large subset of
tumours (12%)withareasofbothpositiveandnegative immunoreactivity, inonly fourofwhichapotentially func-
tion-altering mutation was detected. Regions of differential expression were contiguous and showed similar
morphological phenotype in all cases. Microdissected positive and negative areas from one tumour showed
an inactivating mutation to be present only in the negative area, suggesting intra-tumoral sub-clonal genomic
evolution. Our findings indicate that loss of STAG2 function plays a more important role in non-invasive than
that in muscle-invasive bladder cancer and suggest that cohesin complex-independent functions are likely to
be important in these cases.
INTRODUCTION
Inactivating mutations in the cohesin complex component
STAG2 have been reported in 5.9% of glioblastoma and at
lower frequency in melanoma and Ewing’s sarcoma (1) and
several other cancer types [COSMIC; cancer.sanger.ac.uk/ca
ncergenome/projects/cosmic/].
Cohesin is a four-subunit ring-shaped complex, comprised in
mammalian cells of SMC1, SMC3, RAD21 and STAG1 or
STAG2. The complex mediates cohesion between sister chro-
matids following DNA replication to ensure correct chromo-
somal segregation. Loading of cohesin onto chromatin occurs
during the G1 phase of the cell cycle, and the complex
becomes tightly closed during DNA replication to maintain
chromatid cohesion. During prophase of mitosis, all cohesin
apart from that at the centromeres is removed. Finally, in ana-
phase, centromeric cohesin is removed to allow chromosome
segregation (2). In vertebrates, cohesin complexes contain-
ing STAG1 and STAG2 fulfil distinct functions in chromatid
cohesion, STAG1-cohesin mediating telomere cohesion and
STAG2-cohesin mediating centromeric cohesion. Loss of either
STAG1 or STAG2 has been associated with the generation of an-
euploidy in mammalian cells. For example, STAG1-deficient
mouse embryo fibroblasts show increased aneuploidy (3), and
functional assays in glioblastoma cell lines have linked loss of
STAG2expression to chromatid cohesion defects and aneuploidy
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(1). These data suggest that STAG2may function as a ‘caretaker’
tumour suppressor gene, leading tochromosomal instabilitywhen
inactivated.
In addition to the well-documented functions during cell div-
ision, cohesin also plays a role as anorganizer of interphase chro-
matin. STAG1-cohesin has been most studied in this context. It
has a role in restricting gH2AX accumulation at double-strand
breaks to allow continued expression of neighbouring genes,
and it co-localizes at many sites with CCCTC-binding factor
(CTCF) and other transcriptional regulators, where it plays a
role in regulating gene expression. Evidence to date suggests
that these roles are mainly related to STAG1-cohesin [reviewed
in (4)] and indeed, repair of inactivatingSTAG2mutation togen-
erate normal expression in glioblastoma cells was recently
reported to have no significant effect on the transcriptional
profile, suggesting that the role of STAG2 may be restricted to
its functions in chromatid cohesion (1). However, as STAG2 is
more abundant than STAG1 and can directly bind to CTCF
(5), and as CTCF interactions are cell context-specific, non-
chromatid cohesion-related effects of STAG2 loss appear
likely in some cell types.
The COSMIC database (http://cancer.sanger.ac.uk/ca
ncergenome/projects/cosmic/) lists 11 missense, splicing or
nonsense mutations in STAG2 in bladder cancer (25.7.13, date
last accessed). Eight of these are in 104 muscle-invasive
tumour samples included in the TCGA study of advanced
bladder cancer (http://cancergenome.nih.gov/cancersselected/
invasiveurothelialbladder), and three in muscle-invasive or
superficially invasive tumours from the study of Gui et al. (6).
Such tumours are commonly highly aneuploid. However,
bladder cancers comprise at least two distinct groups, with
marked differences in molecular profiles. The majority of
bladder tumours at presentation are low-grade non-invasive
tumours, most ofwhich are genomically stablewithminimal an-
euploidy (7,8). During exome sequencing of a small panel of
such non-invasive bladder tumours (stage Ta), we identified
several inactivating mutations in STAG2 (Hurst et al., unpub-
lished data). As these samples showed minimal copy number
alterations by array-based CGH, loss of a chromatid-related
cohesin function was unexpected. Therefore, we have carried
out a mutation analysis of the entire coding sequence of
STAG2 and assessed STAG2 protein expression in a large
panel of bladder cancers and cell lines. Here we report the muta-
tion spectrum and the relationship of loss of STAG2 expression
with gender, tumour grade, stage and chromosomal stability.
Our data suggest that loss of STAG2 function plays a more im-
portant role in non-invasive than in muscle-invasive bladder
cancer and that cohesin complex-independent functions are
likely to be important in these cases.
RESULTS
Mutation of STAG2 is frequent in urothelial carcinoma
STAG2has33coding exons,whichencode a141-kDprotein. It is
alternatively spliced both in the 5′ UTR and in the coding region
by inclusion or exclusion of exon 33. We scanned the entire
coding sequence using high-resolution melting (HRM) in 307
bladder tumours and 47 tumour cell lines. STAG2 maps to the
X chromosome (Xq25) and is present as only a single copy in
males. As HRM relies on the presence of wild-type sequence
to generate mutant/wild-type heteroduplexes with aberrant
melting profiles, mutations in pure tumour DNA from males
may not be detected. Therefore, a workflow was devised (Sup-
plementary Material, Fig. S1) that incorporated re-analysis fol-
lowing ‘spiking’ with normal DNA of all male samples that
did not show aberrant melting profiles on first analysis. Cell
lines were all analysed in the presence of added normal DNA.
In the initial screening, variants were identified in 69 tumours
and 8 cell lines (92-1, 94-10, HCV29, U-BLC1, UM-UC3,
UM-UC14, VM-CUB-1 and VM-CUB-3). One hundred and
sixty-eight apparently wild-type samples from male patients
were then re-screened in the presence of normal DNA, and this
revealed an additional 10 variants. Variants in tumour tissues
were confirmed as somatic by comparison with constitutional
DNA from the same patient. Four tumours and one cell line con-
tained two variants. In tumours, we identified 27 nonsensemuta-
tions. In tumours 990 and 1474, the change to theDNA sequence
is a short deletion, which results in immediate termination of the
reading frame without any frameshifted sequence. Twenty-two
tumours had insertion/deletion mutations, which resulted in a
frameshift, and one tumour had an in-frame deletion located
within the STAG domain. In cell lines, one nonsense and one
frameshift mutation were detected, each caused by small
indels (Table 1; Supplementary Material, Table S1).
Mutations at consensus splice sites were found in several
tumours and cell lines. These comprised eight point mutations
in invariant nucleotides, two in conserved nucleotides and six
deletions that encompassed invariant nucleotides. One cell
line, VM-CUB-1, had a duplication of the 3′ splice site of exon
28. Several samples had somatic intronic variants that were not
within splice site sequences. In each case, the potential for an
effect on splicing was assessed using the SSPNN splice site pre-
diction tool (http://www.fruitfly.org/seq_tools/splice.html). No
plausible effect was identified for intronic variants in tumours
1473 and 500 or cell line U-BLC1, so these variants were
regarded as passenger variants and not considered further. The
variants in tumours 1046, 1072 and 987 were regarded as
having potential to disrupt splicing. Tumours 1231 and 860
had substitutions in the final nucleotides of exons 8 and 26, re-
spectively. This position is the exonic part of the consensus
5′ splice site, so these mutations were considered for a role in
splicing even though they would be missense mutations by
their effect on the primary amino acid sequence. SSPNN in
each case suggested that therewould be adecrease in the strength
of the splice site in the presence of the mutation.
Of the 22 sampleswithmutations that had a potential for a role
in splicing, RNA was available for 19. RT-PCR was carried out
using primers located within exons flanking the exon whose
splice sites were affected by the mutation. RT-PCR products
were analysed by agarose gel electrophoresis and Sanger se-
quencing (Fig. 1A and B; Supplementary Material, Table S4;
SupplementaryMaterial, text). A role in splicing was confirmed
for all except that in tumour 1072, which is therefore regarded as
a passenger variant. The effects on splicing were exon skipping
and/or use of local cryptic splice sites except in one tumour
(1345) inwhich no STAG2RT-PCRproducts could be detected,
although control RT-PCR showed that there was adequate RNA
in the sample. The consequences of thesemutations, incorporat-
ing knowledge from RNA analysis, are given in Supplementary
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Material, Table S4. In three samples, tumours 670 and 945 and
cell line VM-CUB-1, the consequence is in-frame skipping of
an exon (Fig. 1A). All other splicing mutants resulted in prema-
ture truncation apart from the exonic variant in tumour 860,
which produced both an exon-skipped product (and thus prema-
turely truncated) andalso aproduct inwhich themutant exonwas
included. Thus, this mutation may operate at both splicing and
missense levels. Taken together, these data indicate that 67 of
307 tumours examined (21.8%) contained mutations that are
predicted to adversely affect STAG2 function (truncation with
or without frameshift or deletion) (Table 1).
Twelve tumours and one cell line hadmissensemutations, the
functional effect of which are unknown. All were at amino acid
residues that are invariant in all vertebrate species examined
(Homo sapiens, Macaca mulatta, Canis lupus, Bos taurus,
Rattus norvegicus, Mus musculus, Gallus gallus and Danio
rerio). Two missense mutations were present in tumours that
Table 1. Variants identified in STAG2 in bladder tumours and cell lines
Sample Position of variant in
transcripta
Predicted effect
at primary amino
acid sequence
level
Effectb
Tumour
595 c.50 C.G p.S17∗ Nonsense
1052 c.256 G.T p.E86∗ Nonsense
1145 c.367 C.T p.Q123∗ Nonsense
1436 c.367 C.T p.Q123∗ Nonsense
359 c.385+1 G.T p.? Splice
(presumed)
1046 c.386-8 A.G p.? Splice
(presumed)
1167 c.407_414 del8 p.F136fs Frameshift
1231 c.462 G.C p.? Splice
315 c.499 C.T p.Q167∗ Nonsense
1025 c.605 C.A p.S202∗ Nonsense
991 c.625_642 del18 p.D209_A214del In-frame
deletion
385 c.739 C.T p.Q247∗ Nonsense
985 c.775 C.T p.R259∗ Nonsense
868 c.809 dupA p.R271fs Frameshift
1332 c.832 C.T p.Q278∗ Nonsense
1383 c.1017+1_1017+22
delinsCATCTTAC
p.? Splice
1474 c.1036 A.C;
c.2707_2710 del4
p.K346Q;
p.T903∗
Missense;
nonsense
811 c.1044 dupT p.T349fs Frameshift
717 c.1071_1072 delCA p.N357fs Frameshift
582 c.1113 C.G p.F371L Missense
1473 c.1117-34 C.T p. (¼) No effect
1175 c.1196+4 A.G p.? Splice
494 c.1347_1351 del5 p.R451fs Frameshift
1696 c.1354_1387 del34 p.G452fs Frameshift
1116 c.1374 delC p.N459fs Frameshift
322 c.1401 delinsTG p.F468fs Frameshift
1135 c.1401 delinsTG p.F468fs Frameshift
987 c.1417-7 A.G p.? Splice
865 c.1444 dupG p.D482fs Frameshift
1063 c.1505 del T p.L502fs Frameshift
1072 c.1534+24 T.A p.¼ No effect
1345 c.1535-40_1566 del72 p.? Splice
1415 c.1549 C.T p.Q517∗ Nonsense
454 c.1580_1581 dupGT p.T528fs Frameshift
869 c.1591 delC p.Q531fs Frameshift
1298 c.1693 G.T p.E565∗ Nonsense
1017 c.1811 G.T p.R604L Missense
1028 c.1815A.C; c.2655
C.T
p.L605F; p. (¼) Missense;
synonymous
417 c.1866_1884 del19 p.K622fs Frameshift
1465 c.1908 C.A p.Y636∗ Nonsense
525 c.1958 C.G p.S653∗ Nonsense
1338 c.1988 A.G p.D663G Missense
961 c.2026-1 G.T p.? Splice
1529 c.2056 C.T p.Q686∗ Nonsense
736 c.2097-3 C.G p.? Splice
1214 c.2097-2 A.G p.? Splice
(presumed)
1210 c.2097-1 G.A p.? Splice
271 c.2201 T.C p.L734P Missense
983 c.2207_2211 del5 p.C736fs Frameshift
990 c.2208_2219 del12 p.C736∗ Nonsense
339 c.2212 C.T p.H738Y Missense
536 c.2229 G.A p.W743∗ Nonsense
945 c.2256_2265+16 del26 p.? Splice
1185 c.2279 delinsCT p.R760fs Frameshift
1053 c.2308 C.T p.Q770∗ Nonsense
Continued
Table 1. Continued
Sample Position of variant in
transcripta
Predicted effect
at primary amino
acid sequence
level
Effectb
860 c.2533 G.A p.? & p.D845N Splice and
missense
1142 c.2534-4_2550 del21 p.? Splice
1079 c.2542 C.T p.Q848∗ Nonsense
670 c.2775+2 delT p.? Splice
1083 c.2822 C.G p.S941∗ Nonsense
1073 c.2848 G.A p.E950K Missense
989 c.2888 A.G p.Q963R Missense
1273 c.2924+1 G.A p.? Splice
1111 c.2977 C.T; c.3085
C.T
p.P993S;
p.Q1029∗
Missense;
nonsense
500 c.3054-15 C.T; c.3085
C.T
p. (¼); p.Q1029∗ No effect;
nonsense
1294 c.3063 C.G p.Y1021∗ Nonsense
140 c.3074 delT p.F1025fs Frameshift
137 c.3085 C.T p.Q1029∗ Nonsense
511 c.3097 C.T p.R1033∗ Nonsense
1434 c.3133 C.T p.R1045∗ Nonsense
643 c.3143 delT p.L1048fs Frameshift
397 c.3153_3154 dupTG p.G1052fs Frameshift
1335 c.3190_3191 delinsT p.S1065fs Frameshift
578 c.3278-3_3296 del22 p.? Splice
1081 c.3364 dupA p.T1122fs Frameshift
529 c.3407_3410 dup4 p.S1137fs Frameshift
1324 c.3448 C.G p.Q1150E Missense
1094 c.3644 C.G p.S1215∗ Nonsense
1172 c.3772 A.G p.M1258V Missense
Cell line
UM-UC14 c.-32 G.A; c.2026-1
G.T
p.?; p.? Unknown
effect; splice
VM-CUB-3 c.289-2 A.G p.? Splice
U-BLC1 c.1731+28 A.C p.¼ No effect
HCV29 c.1756 dupA p.T586fs Frameshift
94-10 c.2097-2 A.G p.? Splice
VM-CUB-1 c.2674-6_2686 dup p.? Splice
UM-UC3 c.2947_2948 delinsT p.K983∗ Nonsense
92-1 c.3787 C.G p.L1263V Missense
aNM_001042749 (numbered with A of ATGi as nucleotide 1).
bSplice mutations supported by RNA evidence unless indicated otherwise.
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also contained nonsense mutations (tumours 1474 and 1111).
The location of mutations is shown in Fig. 1C and their distribu-
tion by type in Fig. 2A.
STAG2mutation is associated with low tumour grade
and stage and with female gender
We assessed the relationship of STAG2 mutation with tumour
grade, stage and patient gender. As there is uncertainty about
the effect of missense mutations on protein function, these ana-
lyseswere all carried out twice, firstwith only inactivatingmuta-
tions included and then including all mutations. There was a
significant association with low tumour grade (Fisher’s exact
test, P ¼ 0.0002 and P ¼ 0.0023, respectively) and with lower
tumour stage (chi-square test, P ¼ 0.001 and P ¼ 0.044, re-
spectively) (Fig. 2C). Inactivating mutation was also signi-
ficantly associated with female gender (Fisher’s exact test,
P ¼ 0.042) (Fig. 2B) but not when missense mutations were
included in the analysis (Fisher’s exact test, P ¼ 0.073). We
examined the relationship of mutation status with disease
recurrence (median follow-up, 81 months). No significant rela-
tionships were uncovered when inactivating mutations only or
all mutations were included [hazard ratio ¼ 1.14 (P ¼ 0.53)
and 1.34 (P ¼ 0.15) for all tumours, 1.04 (P ¼ 0.92) and 1.32
(P ¼ 0.49) for stage T1+ ≥T2 tumours and 1.25 (P ¼ 0.38)
and 1.46 (P ¼ 0.13) for stage Ta tumours].
Figure1.STAG2mutations in bladder cancer samples. STAG2splice sitemutations in (A) cell lineVM-CUB-1and (B) bladder tumour 1231.Left-hand panels in (A)
and (B) show aberrantly sized bands generated by RT-PCR, and right-hand panels show nucleotide sequences of aberrant RT-PCR products illustrating the effects of
splicing mutations at the RNA level. (A) PCRwas performed on VM-CUB-1 cDNA using primers in exons 27 and 29. A PCR product 102 bp smaller than that gen-
erated using cDNA from normal human urothelial cells (NHUC) was observed for VM-CUB-1. Sanger sequencing of RT-PCR products showed that this aberrantly
sized band lacked exon 28. Bladder tumour 670 carries a splice site mutation that is also predicted to result in skipping of exon 28, and this sample generated a PCR
product similar in size to that observed forVM-CUB-1. Sequencing confirmed that this PCRproduct also lacked exon 28 (data not shown). (B) PCRwas performedon
cDNA frombladder tumour 1231 using primers in exons 7 and 9.APCRproduct 77 bp smaller than that generated using cDNA fromNHUCwas observed for tumour
1231, and sequencing confirmed that the aberrantly sized PCR product lacked exon 8. A detailed description of splice site mutations in all samples is given in Sup-
plementary Material, text. (C) Diagram of STAG2 protein showing position of somatic nonsense, missense, splicing, frameshift and indel mutations identified in
bladder tumours. STAG and SMC (structural maintenance of chromosomes) domains are also shown.
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We also tested for association between STAG2 mutation and
FGFR3, PIK3CA, TP53 and RAS gene mutation (7). These tests
were carried out both with and without inclusion of STAG2mis-
sense mutations. In both cases, mutation was significantly asso-
ciated with FGFR3 mutation (Fisher’s exact test, P ¼ 1.16 ×
1025 and 8.82 × 1027, respectively) and with PIK3CAmutation
(P ¼ 0.0048and0.0067, respectively)but notwithRASgenemu-
tation (P ¼ 0.507 and 0.818, respectively). Mutations were sig-
nificantly associated with wild-type status for TP53 only when
missense mutations of STAG2 were not considered (P ¼ 0.032).
In the cell lines that were found to contain a mutation, mutation
status for FGFR3, PIK3CA, RAS genes and TP53 was available
but the same relationships were not found. Two of these lines
contain anFGFR3mutation (94-10 andUM-UC14), one contains
a KRASmutation (UM-UC3), two contain mutations in PIK3CA
(VM-CUB-1 and VM-CUB-3) and six have mutations in TP53
(all except 94-10 and HCV29) (Supplementary Material,
Table S5). This high frequency of TP53 mutation differs from
that in the tumour population in which we detected STAG2muta-
tions. As the majority of available urothelial carcinoma (UC) cell
lines arederived frominvasive tumours, including thefiveSTAG2
mutant cell lines forwhich stage and/or grade information is avail-
able, they are not representative of the spectrumofUC in general.
STAG2 mutation is not associated with chromosomal copy
number alterations
Previously, loss of STAG2 function was reported to be
associated with generation of aneuploidy (1). As low-grade,
low-stage bladder tumours are frequently near-diploid, the asso-
ciation of inactivating mutation with these features was not
anticipated. BAC array CGH data were available for 220 tumo-
urs [(7) and unpublished data]. To gain a more accurate assess-
ment of the relationship of STAG2 mutation with genomic
instability, we tested the relationship of mutation with genome-
wide copy number alterations measured as fraction of genome
altered (FGA; percentage of clones on the array that reported sig-
nificantly altered copy number). Lower mean FGAwas found in
STAG2mutant tumours (t-test,P, 0.001) (Fig. 3A).When sub-
dividing by stage or grade, significantly lower FGAwas found in
stage Ta (t-test, P ¼ 0.006) and grade 2 (t-test, P ¼ 0.014)
STAG2 mutant tumours (Fig. 3B and C). To provide a better
measure of aneuploidy, we examined the number of whole
chromosome copy number alterations in this dataset (Supple-
mentaryMaterial, TableS1).Thismeasurewasalso significantly
lower in tumourswith STAG2mutation (Mann–WhitneyU-test,
P, 0.002) (Fig. 3D). When subdividing by tumour stage, this
Figure 2. STAG2mutation types and relationship to patient gender, tumour grade and stage. (A) Pie chart showing distribution of mutation types. (B) Distribution of
mutations in relation to gender. (C) Distribution of mutations in relation to tumour grade and stage.
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was also significantly lower in Ta and grade 1/2 tumours (P ¼
0.03; P ¼ 0.039).
Intra-tumour heterogeneity in STAG2 protein expression
Immunohistochemistrywith amousemonoclonal antibody raised
against recombinant human STAG2 was used to assess STAG2
protein expression in all tumours for which formalin-fixed,
paraffin-embedded (FFPE) blocks were available (n ¼ 120). Of
these, 15 had been shown to contain nonsense or frameshift muta-
tions, 6 containedmutations shown or predicted to affect splicing,
1 had an intronic variant predicted to have no effect and 5 con-
tained missense mutations (Supplementary Material, Table S1).
The specificity of the antibody used has been confirmed
previously(1).Normalbladderandureterusedaspositivecontrols
showed strongnuclear staining in all urothelial cell layers (Fig. 4),
and all tissues showed strong nuclear staining in stromal cells,
which provided an internal positive control.
Of the 15 tumours with nonsense or frameshift mutations,
11 showed no detectable STAG2 protein, 2 showed positive
staining and 2 contained both positive and negative areas (Sup-
plementaryMaterial, Table S1). DNAwas extracted fromwhole
FFPE sections of the two tumours with positive staining and
frameshift (454) or nonsense (500)mutation and frommicrodis-
sected regions of positive and negative staining from 1 (1298) of
the 2 with positive and negative areas. The second of these
(1094) had insufficient tissue in the FFPE block. Primers were
designed to amplify short products containing the known var-
iants found in each tumour, and the products were sequenced.
Neither of the positively-staining cases contained the mutation
found in the fresh-frozen sample (data not shown). In case
1298, with positive and negative staining, the mutation was
detected in the negative part of the section but not the positive
part, indicating genomic heterogeneity within this tumour
(Fig. 4).
Of the six tumours with mutations that affect splicing, four
showed loss of expression, one showed positive staining and
one showed both positive and weakly staining areas. FFPE
tissue was available for mutation analysis for the sample with
positive staining (359), and this showed absence of the splicing
mutation that had been detected in the related fresh-frozen
sample. All five tumours with missense mutations showed posi-
tive staining, twoofwhich (271and1338) alsohadareas of tissue
with no expression. FFPE tissue from all of these was microdis-
sected and examined for the presence of the missense mutation.
In the twosampleswithpositive andnegative areas, bothpositive
Figure 3.Relationship of STAG2mutation with copy number alterations. Box plots showing the relationship between FGA andmutation status in (A) tumours of all
stages and grades, (B) stage Ta tumours and (C) grade 1/2 tumours. The top and bottom of the boxes represent the 75 and 25% percentiles, respectively. Whiskers
represent 1.5 times the upper and lower quartile limits, unless this exceeds the range of the data in which case whiskers extend from maximum to minimum
values. Black lines represent medians. Outliers are shown as open circles. (D) Histogram showing whole chromosome copy number alterations in STAG2wild-type
(grey bars) and mutant (black bars) bladder tumours.
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and negative areas were examined in one and only positive areas
in the other. Mutation was detected in all samples analysed, in-
dicating that none of thesemissensemutations affect protein sta-
bility. IHC data were not available for the three tumours (670,
945 and 991), which had mutations that directly or indirectly
result in in-frame deletion.
Interestingly, three tumours in which no mutation was
detected showed complete absence of expression and a further
nine showed chimeric staining pattern with both positive and
negative areas. In total, 14 of 120 tumours analysed by immuno-
histochemistry (12%) showed chimeric staining pattern, only 2
of which contained clearly inactivating mutations. In all of
these cases, there was clear contiguity between positive and
negative areas, with adjacent areas showing strong positivity
or complete absence of staining. Tissue morphology was identi-
cal, and there was no indication that two separate tumoursmight
be present and intermixing (Fig. 4).
We examinedSTAG2expression in all 47 tumour cell lines by
immunoblotting (Fig. 5). This confirmed the absence of
expression in five lines with predicted inactivating mutations.
The sixth line (VM-CUB-1) with a mutation that had been con-
firmed to affect splicing (Fig. 1; Supplementary Material,
Table S4) showed protein expression. RT-PCR data showed
that this resulted in in-frame deletion of exon 28 (35 amino
acids). As this protein would not have a premature truncation,
it may be stable and retain some function. MGH-U3, in which
no mutation was detected, showed a very low level of STAG2
protein expression.
DISCUSSION
We have identified a high frequency of inactivating mutation of
STAG2 in bladder cancer, with a significant associationwith low
tumour grade and stage. Mutations were found in 32.6% of Ta
tumours, and in 24.7% of bladder tumours overall. This repre-
sents the highest frequency of STAG2 mutation detected in any
cancer to date. A previous study reported absence of STAG2
Figure4.STAG2expressiondetectedby immunohistochemistry innormalureteric urotheliumandurothelial carcinoma. (A)Normal ureter. (B)Urothelial carcinoma
with wild-type STAG2 sequence and normal protein expression. (C) Tumour 643 (p.L1048fs) showing absence of expression in tumour cells and positive staining in
stroma. (D) Tumour 511 (p.R1033∗). (E) Tumour 961 with splicingmutation (c.2026-1 G.T). (F) Tumour 866with chimeric staining pattern. (G–I) Sections from
tumour 1298. (G) Areas with absence of expression containing inactivating mutation (c.1693 G.T; p.E565∗; arrow). (H) Area of positive staining containing wild-
type sequence. (I) Detail showing contiguity of positive and negative staining.
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protein expression in cell lines derived from a range of cancers
(glioblastoma, Ewing’s sarcoma,melanoma, haematologic, cer-
vical and renal) and identifiedmutationsor homozygousdeletion
in several of these. In tumours, mutations were identified in 4 of
68 glioblastomas (5.8%), a melanoma and a Ewing’s sarcoma.
The COSMIC database (25.7.13, date last accessed) lists only
57 confirmed somatic mutations in 7086 samples from a range
of tumour types.
The high frequency of inactivating mutation in bladder can-
cer implies a cell type-specific effect of loss of function in the
urothelium. In non-muscle-invasive tumourswheremutationwas
most frequent, mutations in the promoter of telomerase (TERT)
(.80%) (9,10) and activating mutations in FGFR3 (≏70%)
(11) are the most common events recorded to date. Mutations in
PIK3CA, the catalytic subunit of phosphatidylinositol-3 kinase
(PI3K), are found in 20–30% of cases (12). As expected, given
the association of STAG2 mutation with low tumour grade and
stage, we also found significant association with these other mu-
tational events in the non-invasive tumour group. The lower fre-
quencyofmutationor loss of expression found inbladder tumour
cell lines is compatible with their origin from muscle-invasive
bladder cancers in virtually all cases.
The vast majority of the 79 somatic mutations identified in
tumour tissues were inactivating (nonsense, frameshift or spli-
cing). Nonsense and frameshift mutations were distributed
throughout the gene and regardless of position were associated
with loss of protein expression in those cases where we were
able to carry out immunohistochemistry, possibly caused by
nonsense-mediated decay of the mRNA. A cluster of inactivat-
ing mutations (n ¼ 10) was located in exon 31 between codons
1021 and 1065 (Table 1) the significance of which is not
known. Phosphorylation sites have been identified at residues
S1058, S1064 and S1065 and in the region C-terminal to this
cluster (13). The C-terminal region also harbours putative
nuclear localization signals (14). None of the missense muta-
tions identified here affected these residues or any residues
within the three LXXL motifs that show homology with tran-
scriptional co-activators of the p160 family, one of which is
implicated in ability of STAG2 to co-activate specific transcrip-
tion factors (15).
The significance of the missense mutations identified is not
clear. STAG2 protein sequence is highly conserved, and all resi-
dues affected by mutation are identical in vertebrates. This high
level of conservation could indicate possible functional conse-
quences of these alterations, although in several cases the
changes were conservative. Here we tested for associations
with grade, stage, gender and other mutations both with and
without these mutations included, owing to this uncertainty. In
no case did inclusion or exclusion of these affect the significance
of the associations found. As this is a large protein and the mis-
sense mutations identified here show no clustering in specific
regions of the protein or affect residues with known function,
it is possible that they represent passenger mutations. Of the 57
somatic mutations recorded in the COSMIC database, 65% are
missense and only 19% nonsense. We were able to assess
protein expression in 5 of the 10 tumours with missense muta-
tion. As all retained expression, we conclude that they do not
affect protein stability. Functional studies will be required to
assess their significance fully.
Overall we identified 3 tumours with complete absence of ex-
pression and12with chimeric staining that hadnomutation iden-
tified. HRM is restricted to the detection of variants that can be
amplified by PCR. Thus, large genomic deletions, such as that
reported in U138MG by Solomon et al. (1), would not be
detected by this technique, nor would smaller deletions where
one or both of the deletion breakpoints are outside the region
coveredby thePCR.Furthermore,HRM, like anymutation scan-
ning technique, has a mutation detection sensitivity of ,100%
(16). In a study that used single-strand conformation polymorph-
ism analysis to search formutations in colorectal, gastric, breast,
non-small cell lung and prostate carcinomas (17), no mutations
were identified but significant numbers of gastric, colorectal
and prostate cancer samples showed absence of protein expres-
sion by immunohistochemistry. Further work is needed to
assess other potential mechanisms of loss of expression. As
STAG2 has a CpG island in its promoter region, promoter hyper-
methylation is one possibility.
The frequencyof chimeric expressionpattern found inbladder
tumours suggests that intra-tumour genomic evolution com-
monly involves loss of STAG2, even in low-grade, low-stage
tumours, which are generally considered to represent an evolu-
tionarily stable sub-group. We were able to confirm this
genomic heterogeneity in one case where a known mutation
could be detected. As the gene is large, it was not feasible to
test for mutation in small microdissected tumour areas with
lack of expression when no mutation had been found in the
gross sample. Whole-genome amplification from such samples
may allow clarification of the status of such tumours in future.
The finding of a higher frequency of mutation in females
requires replication in an independent study. To date no other
molecular features have been shown to differ between the
bladder tumours of men and women. UC incidence is higher in
males, but women tend to present later and their outcomes are
less favourable (18), making gender an important factor in clin-
ical decision making for UC management. The basis for the
gender-related difference in incidence has not been precisely
ascertained. Expression of the androgen receptor has been sug-
gested to play a role not only in the development of the higher in-
cidence of bladder cancer in males but also in determination of
prognosis, although some conflicting results have been reported
[reviewed in (19)]. It will be of interest to examine STAG2mu-
tation in relation to both gender and the status of androgen recep-
tor and its targets.
Figure 5. Immunoblot showing STAG2 expression in bladder tumour-derived
cell lines. Proteins (30 mg) from 47 cell lines were analysed by western blot ana-
lysis using antibodies specific to STAG2. Asterisks denote cell lines carrying
STAG2mutations. Alpha-tubulin expression was used to assess protein loading.
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Our data indicate that loss of STAG2-cohesin function in me-
diating chromatid cohesion is unlikely to be the major effect of
mutational inactivation in bladder cancer. Whole chromosome
copy number alterations measured by array CGH showed an
inverse relationship to STAG2 mutation. As is widely reported,
these were more common in tumours of high grade and stage
where STAG2mutationwas less common.Cohesin is also impli-
cated in DNA repair where it mediates chromatid cohesion to
allow repair of DNA double-strand breaks by homologous re-
combination. Again, defects in this process are predicted to
lead to genomic instability, and our data showed an inverse rela-
tionship to sub-chromosomal copy number alterations, which
could implicate this function. Thus, we hypothesize that the
loss of STAG2 in the context of non-invasive bladder cancer
has major impact on a cell-cycle and DNA repair-independent
function.
Apart from the distinct roles of STAG1 and STAG2 in medi-
ating telomere and centromere cohesion, respectively, only very
recently has there been any information on functions of STAG1
and STAG2 that are either specific or redundant. Although
STAG2 ismore abundant in cells than STAG1, unique functions
have not yet been reported. Some specific roles for STAG1 have
been described following generation of STAG1 knockout mice,
and results indicate that STAG2 cannot fulfil all functions of
STAG1 (3,20). Results in STAG1-null cells indicate that
STAG2-cohesin lacks ability to accumulate at promoters and
shows reduced overlap with overall CTCF distribution com-
paredwithSTAG1-cohesin. Thedevelopment ofSTAG2knock-
out mice may clarify which, if any, of the many functions of
cohesin specifically involve STAG2. These functions have
been reviewed recently [(21,22)].
In the recent study of STAG2 in glioblastoma, a clear effect of
STAG2 loss of function on the generation of aneuploidy was
found (1). In this tumour type, transcriptional analysis of
paired cell lines with and without STAG2 expression revealed
no expression differences. In bladder, where no cohesin-related
effect appears to result from loss of STAG2, an effect on tran-
scription must be considered as an alternative possibility and
now merits examination.
MATERIALS AND METHODS
Patient samples and DNA isolation
The study was approved by the Leeds-East Research Ethics
Committee (99/156), andwritten informed consentwasobtained
from all patients. Cold cup biopsies of UCwere collected, snap-
frozen and stored in liquid nitrogen. The remainder of the tissue
was embedded in paraffin for diagnostic assessment. The tumour
panel consisted of 307 samples. Two hundred and ninety-seven
were transitional cell carcinoma, eight were squamous cell car-
cinoma and two were small cell carcinoma. The transitional cell
tumours comprised 4 pTaG1, 109 pTaG2, 25 pTaG3, 14 pT1G2,
62pT1G3, 3 pT2G2, 67≥pT2G3and11G2and twoG3 tumours
with nounderlying stroma (pTx) (23,24) (SupplementaryMater-
ial, Table S1). Clinical data were collected from 232 patients.
DNA was extracted from frozen sections containing ≥70%
tumour cells and venous blood samples as described previously
(12) and from FFPE tissue sections using a QIAampDNAFFPE
Tissue Kit (Qiagen).
Urothelial cell lines
Forty-sevenUCcell lines (253J, 5637, 639V, 647V, 92-1, 94-10,
96-1, 97-1, 97-18, 97-24, 97-7, BC3C, BFTC905, BFTC909,
CAL29, DSH1, HCV29, HT1197, HT1376, J82, JMSU1,
JO’N, KU-19-19, LUCC1, LUCC2, LUCC3, LUCC4,
LUCC5, LUCC6, LUCC7, LUCC8, LUCC9, MGH-U3,
RT112, RT4, SCaBER, SD, SW780, SW1710, T24, TCCSUP,
U-BLC1, UM-UC3, UC-UC14, VM-CUB-1, VM-CUB-2 and
VM-CUB-3) were investigated (Supplementary Material,
Table S2). Telomerase-immortalized normal human urothelial
cells (NHUC) (25) were used as controls. Cell line identity
was verified by short tandem repeat DNA typing using Power-
plex 16 kit (Promega). Profiles were compared with publically
available data (ATCC and DSMZ), to matched patient samples
(for LUCC1-LUCC9) or, where no reference profile was avail-
able,were confirmed as unique.DNAwas extracted as described
previously (12).
STAG2 mutation analysis
Whole-genome amplificationwas carried out using theREPLI-g
Mini kit (Qiagen) on DNA extracted from fresh-frozen tum-
our tissue samples. The entire coding sequence of STAG2 and
flanking intronic sequence was screened for variants using
HRM analysis followed by bidirectional sequencing (16).
Primers (Supplementary Material, Table S3) were designed
using Primer3; http://frodo.wi.mit.edu/primer3/input.htm. The
predicted melting profile of the PCR products was determined
using DHPLCMelt (http://insertion.stanford.edu/melt.html),
and in some cases, primers were redesigned or had short GC
clamps added to make melting profiles as simple as possible.
PCR forHRMwas carried out in 10 ml reactions overlaidwith
20 ml ofmineral oil. Each reaction contained 1× AcquaMaster-
Mix (www.acquascience.com), 1× LCGreen+ (www.acqua
science.com), 4 pmol of each primer and 1.5 ml of WGA DNA
diluted 1/200 with TE. Cycle parameters were 95 8C for
15 min and then 45 cycles of 95 8C for 10 s, annealing for 15 s
(59–618C depending on primer pair) and 72 8C for 15 s; after
a final denaturation at 94 8C for 30 s, reactions were cooled to
25 8C at 0.18C/s to promote heteroduplex formation. HRM
(16) was carried out using a HR96 LightScanner (www.acqua
science.com). All samples with melting profiles that differed
from wild-type samples were bi-directionally sequenced.
Tumour samples frommale patients inwhich nomutationwas
identifiedon initial screeningwere re-screenedafter spikingwith
DNA fromamalewild-type control sample to a concentration of
≏20% of amplifiable templates in the spiked sample. Cell line
DNA samples were all screened after spiking with 15% of wild-
type control DNA from a female sample.
PCR from FFPE sections was carried out in 10 ml reactions
containing 1× HotStarTaq mastermix (Qiagen), 4 pmol of
each primer and 1 ml of FFPE DNA. Cycle parameters were
95 8C for 15 min and then 40 cycles of 95 8C for 30 s, annealing
for 30 s (50–568C depending on primer pair) and 72 8C for 30 s
followed by 72 8C for 10 min.
Sequencing was performed using a Big Dye Terminator
Ready Reaction Mix v1.1 kit and primers described in Supple-
mentary Material, Table S3. Data were collected using an
Applied Biosystems 3130xl Genetic Analyser. Data were
1972 Human Molecular Genetics, 2014, Vol. 23, No. 8
analysed by visual inspection of electropherograms and using
Mutation Surveyor software (SoftGenetics, Inc.).
For 78 of 79 tumour samples containing variants, the variant
was confirmed in a second PCR using DNA that had not been
whole-genome-amplified. One variant (tumour 1135) was con-
firmed in a second PCR from whole-genome-amplified DNA.
Somatic mutation status in tumours was confirmed by analysis
of normal matched blood samples except for samples 271,
595, 991, 1294, 1415 and 1434.
RNA isolation, cDNA synthesis and RT-PCR
Total RNA was extracted from frozen sections containing at
least 70% tumour cells using a PicoPure RNA Isolation Kit
(Nikon UK Limited). cDNA was synthesized using 250–
500 ng of total RNA and Superscript II (Invitrogen) according
to the manufacturer’s instructions. PCR was performed in a
volume of 25 ml containing 1 × PCR buffer, 1.5 mM MgCl2,
0.2 mM dNTPs, 0.2 mM of each primer (see Supplementary Ma-
terial, Table S4), 2.5 units GoTaq DNA polymerase (Promega)
and 5 ml of cDNA (diluted 1 in 5 prior to use). Cycle parameters
were 958C for 5 min and then 45 cycles of 958C for 30 s, 558C
for 30 s and 728C for 30 s followed by 728C for 10 min.
Immunohistochemistry
Tumour tissue sections were deparaffinized in xylene, rehy-
drated and endogenous peroxidase activity blocked in 3%hydro-
gen peroxide. Sections were boiled in 10 mM citric acid buffer
(pH6) for 2 min, non-specific binding was blocked in 1×
casein solution (VectorLaboratories) for 20 min, followedby in-
cubation with primary antibody (1:200; sc-81852; Santa Cruz)
for 1 h at room temperature, detection using the X-Cell Plus
Polymer HRP detection Kit (Menarini Diagnostics), visualiza-
tion with 3,3′ diamino-benzidine terahydrochloride (DAB;
Vector Laboratories) and counterstaining with haematoxylin.
All runs included a no primary antibody control.
Protein extraction and western blot analysis
Cells were cultured to 70–80% confluence and then lysed in
RIPAE buffer (1% Triton X-100, 1 mM EDTA, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulphate in phosphate-
buffered saline) containing protease inhibitors (P8340; Sigma)
and phosphatase inhibitors (P5726; Sigma). Proteins (30 mg)
were separated under denaturing conditions in 7.5% SDS
polyacrylamide gels and then transferred to Hybond-C super
membrane (GEHealthcare Life Sciences). Blots were incubated
with primary antibodies specific to STAG2 (1:1000; sc-81852;
Santa Cruz) overnight at 48C. Horseradish peroxidase-
conjugated secondary antibodies and a Luminata Forte
WesternHRPsubstrate (Millipore)were used for chemilumines-
cent detection of bound antibody. Blots were incubated in strip-
ping buffer (50 mM Tris pH7.5, 10 M urea) for 1 h at 558C and
reprobed with a-tubulin antibodies (1:3000; MCA77G; AbD
Serotec) for the assessment of protein loading.
Statistics
A Fisher’s exact test was used to test for association between
STAG2 mutation status and tumour grade, patient gender and
the mutation status of FGFR3, PIK3CA and RAS [data from
(7) and unpublished data]. Chi-square analysis was used to test
for association with tumour stage. Fraction of genome altered
was as previously defined (7). t-tests were used to test for signifi-
cant differences in FGA between STAG2 mutant and wild-type
samples. AMann–WhitneyU-test was conducted to test for sig-
nificant differences in whole chromosome copy number altera-
tions between STAG2 mutant and wild-type samples. Log-rank
tests were carried out to test for the association between
STAG2mutation status and time to recurrence. As the functional
significance of missense mutations was not clear and it was con-
sidered that they may represent passenger events, all tests were
carried out twice, with these samples designated either mutant
or wild type.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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